I respectfully disagree. I think there are competitors coming (from memory) so Acadia might not be inclined to let them enter the market.
If you already are a name in the community, then providing families with a much better and more tolerable drug would be better than letting a competitor enter the market and steal a share.
If patients transition from Trof to 2591 and they get better outcomes with less side effects, you are less likely to transition to a competitor - at least that would be my take.
NEU Price at posting:
$19.02 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)